Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Bile Acid Derivative Trims Fat from Double Chin

By BiotechDaily International staff writers
Posted on 14 Mar 2013
An injectable drug may help patients get rid of excess submental fat (SMF) without the need for surgery, according to a new study.

Under development by Bayer Healthcare (Munich, Germany) and Kythera Biopharmaceuticals (Calabasas, CA, USA), the investigational agent ATX-101 is a synthetically-derived deoxycholic acid that prompts adipocytolysis, the permanent destruction of the fat cell. In an interim analysis of ongoing phase III trials, which enrolled 2,500 participants, in which 1,500 have been given the drug and 1,000 have received placebo, the participants reported 87% satisfaction with the results.

To assess long-term safety and efficacy, the phase IIIb study conducted at 21 sites in the US over 12 months enrolled 165 patients with moderate SMF who reported being dissatisfied with the appearance of their face and chin; 78% were female and mean age was 47. All patients had a history of stable body weight and no prior interventions to treat their double chin. All received 2 mg/cm2 of the drug by subcutaneous microinjections with a 30-gauge needle directly into preplatysmal SMF for up to six treatment sessions at 28-day intervals.

The results of the interim analysis at week 32 showed that 86.8% of patients achieved greater than a one-point improvement on the clinician-reported SMF rating scale from baseline through 12 weeks after the last treatment. Patients also reported subjective improvement, with 83% having achieved at least a one-point improvement in self-reported SMF rating scores. The treatment also received high marks for other patient-reported outcomes, including facial appearance, chin and neck definition, and unchanged or improved skin laxity. The results of the study were presented at the American Academy of Dermatology annual meeting, held during March 2013 in Miami Beach (FL, USA).

“Most patients reported feeling less self-conscious and younger, and many patients said they looked like they had lost weight even though their body mass index remained the same,” said study presenter Susan Weinkle, MD, a dermatologist in private practice in Bradenton (FL, USA). “ATX-101 appears to be well tolerated and effective at reducing submental fat, and may very well provide, in the future, an approach to submental fat for our patients who are so unhappy with this part of their body.”

Deoxycholic acid is one of the secondary bile acids secreted by the liver. It is a byproduct derived from the metabolization of chenodeoxycholic acid by intestinal bacteria. In the human body deoxycholic acid is used in the emulsification of fats for the absorption in the intestine. It has, in some countries (including Switzerland) been licensed as an emulsifier in the food industry.

Related Links:

Bayer Healthcare
Kythera Biopharmaceuticals



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.